Company / Return on Assets (ROA)
Inmune Bio, Inc. Return on Assets (ROA) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-130.1%
FY2025
5-year range
-130.1% / -12.1%
FY2021-FY2025
Trend
-71.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has declined for 4 consecutive years, from -12.1% in FY2021 to -130.1% in FY2025.
Based on SEC 10-K filings.
-130.1% in FY2025 with a 5-year CAGR of -111.2%.
Declined from -47.9% to -130.1% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -93.0pp
- 5-Year Change
- -111.2pp
- 10-Year Change
- -
Key checks
Key Insights
- Inmune Bio, Inc.'s return on assets (roa) has declined for 4 consecutive years.
- In FY2025, return on assets (roa) decreased 71.5% year-over-year.
- Peak return on assets (roa) was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -130.1% | -71.5% |
| FY2024 | -75.8% | -58.4% |
| FY2023 | -47.9% | -29.1% |
| FY2022 | -37.1% | -206.3% |
| FY2021 | -12.1% | +35.9% |
| FY2020 | -18.9% | -294.4% |
| FY2018 | -4.8% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026